Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma

AIM: To investigate the feasibility of using bevacizumab to improve the survival of American Joint Committee on Cancer (AJCC) stage III melanoma patients, we investigated how a single bevacizumab treatment affected nodal disease and a panel of biomarkers in clinically fluorodeoxyglucose positron emi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruijff, S., Bastiaannet, E., Brouwers, A. H., Nagengast, W. B., Speijers, M. J., Suurmeijer, A. J. H., Hospers, G. A., Hoekstra, H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Melanomas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264856/
https://www.ncbi.nlm.nih.gov/pubmed/21861214
http://dx.doi.org/10.1245/s10434-011-2027-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264856/
https://www.ncbi.nlm.nih.gov/pubmed/21861214
http://dx.doi.org/10.1245/s10434-011-2027-2

Ejemplares similares